SCHEMBL3876563

SCHEMBL3876563

O=C(Cc1ccccc1)Nc1ccccc1C(=O)Nc1n[nH]c2sc(C(=O)O)cc12

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXFP1 Q9HBX9 1/20 0.46
ALDH1A1 P00352 4/20 0.45
KDM4E B2RXH2 2/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
LMNA P02545 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
CDK2 P24941 7/20 0.43
GPR35 Q9HC97 1/20 0.41
AURKA O14965 1/20 0.41
KDM6B O15054 1/20 0.41
KDM4D Q6B0I6 1/20 0.41
KDM4C Q9H3R0 1/20 0.41
CCNA2 P20248 1/20 0.40
CCNA1 P78396 1/20 0.40
HPGD P15428 2/20 0.40
PKM P14618 1/20 0.40
SIRT2 Q8IXJ6 1/20 0.40
GALR3 O60755 1/20 0.39
HTT P42858 1/20 0.39
RAB9A P51151 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4631768 0.89 CDK2 (0.52) CDK2AURKACCNA2CCNA1CDK1
SCHEMBL3866786 0.85 KDM4E (0.48) RXFP1ALDH1A1KDM4EPKMHTT
SCHEMBL3866586 0.85 POLB (0.42) RXFP1ALDH1A1KDM4ESMN1; SMN2LMNA
SCHEMBL3869847 0.84 MAPK1 (0.49) RXFP1ALDH1A1KDM4ESMN1; SMN2HPGD
SCHEMBL3872653 0.83 ALDH1A1 (0.43) RXFP1ALDH1A1KDM4EL3MBTL1GPR35
SCHEMBL3870804 0.83 NPC1 (0.45) RXFP1ALDH1A1SMN1; SMN2L3MBTL1GPR35
SCHEMBL3866838 0.82 CYP1A2 (0.42) KDM4EL3MBTL1HTT
SCHEMBL3875203 0.82 TSHR (0.51) RXFP1ALDH1A1KDM4ESMN1; SMN2L3MBTL1
SCHEMBL3872706 0.82 KCNMA1 (0.38) RXFP1ALDH1A1KDM4ELMNAL3MBTL1
SCHEMBL3871522 0.81 P2RY14 (0.47) RXFP1ALDH1A1KDM4EHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1904503-B1 1H-THIENO[2,3-C]-PYRAZOLE COMPOUNDS USEFUL AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES SRL (IT) 2013-11-06 EP disclosed
US-20090149457-A1 1H-Thieno[2,3-c]Pyrazole Compounds Useful as Kinase Inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2009-06-11 US disclosed
EP-1904503-A1 1H-THIENO[2,3-C]-PYRAZOLE COMPOUNDS USEFUL AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.r.l. (IT) 2008-04-02 EP disclosed
WO-2007009898-A1 1H-THIENO[2,3-C]PYRAZOLE COMPOUNDS USEFUL AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2007-01-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090149457-A1 1H-Thieno[2,3-c]Pyrazole Compounds Useful as Kinase Inhibitors CCNH, PDK1, MAP3K5 RXFP1 3180/4885ALDH1A1 3557/4885KDM4E 2856/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.